(Q37299503)

19 August 2017

1 reference

title

Treating hepatitis C in the prison population is cost-saving (English)

1 reference

19 August 2017

1 reference

3

Sammy Saab

1 reference

19 August 2017

Jennifer A Tan

1

1 reference

19 August 2017

Tom A Joseph

series ordinal

2

1 reference

19 August 2017

language of work or name

English

0 references

publication date

1 November 2008

1 reference

19 August 2017

1 reference

19 August 2017

volume

48

1 reference

19 August 2017

issue

5

1 reference

19 August 2017

page(s)

1387-1395

1 reference

A framework for management of hepatitis C in prisons

19 August 2017

cites work

1 reference

Hepatitis B, hepatitis C, and HIV in correctional populations: a review of epidemiology and prevention

21 January 2018

1 reference

Hepatitis C virus infection among prisoners in the California state correctional system

21 January 2018

1 reference

Hepatitis C in state correctional facilities

21 January 2018

1 reference

Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population

21 January 2018

1 reference

Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C.

21 January 2018

1 reference

A health economic model to assess the cost-effectiveness of PEG IFN alpha-2a and ribavirin in patients with mild chronic hepatitis C.

21 January 2018

1 reference

Productivity improvements in hepatitis C treatment: impact on efficacy, cost, cost-effectiveness and quality of life

21 January 2018

1 reference

Cost-effectiveness of peginterferon alfa-2b in combination with ribavirin as initial treatment for chronic hepatitis C in Sweden.

21 January 2018

1 reference

A cost-effectiveness analysis of peginterferon alfa-2b plus ribavirin for the treatment of naive patients with chronic hepatitis C.

21 January 2018

1 reference

Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C.

21 January 2018

1 reference

Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation

21 January 2018

1 reference

The economics of treating chronic hepatitis C patients with peginterferon alpha-2a (40 kDa) plus ribavirin presenting with persistently normal aminotransferase.

21 January 2018

1 reference

Cost-utility analysis of different peg-interferon alpha-2b plus ribavirin treatment strategies as initial therapy for naïve Chinese patients with chronic hepatitis C.

21 January 2018

1 reference

Peginterferon alfa-2a versus peginterferon alfa-2b as initial treatment of hepatitis C virus infection: a cost-utility analysis from the perspective of the Veterans Affairs Health Care System

21 January 2018

1 reference

Cost effectiveness of interferon alpha or peginterferon alpha with ribavirin for histologically mild chronic hepatitis C.

21 January 2018

1 reference

The spectrum of chronic hepatitis C virus infection in the Virginia Correctional System: development of a strategy for the evaluation and treatment of inmates with HCV.

21 January 2018

1 reference

Treatment of chronic hepatitis C in a state correctional facility

21 January 2018

1 reference

Classification of chronic viral hepatitis: a need for reassessment

21 January 2018

1 reference

Diagnosis, management, and treatment of hepatitis C

21 January 2018

1 reference

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

21 January 2018

1 reference

Release from prison--a high risk of death for former inmates

21 January 2018

1 reference

Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study

21 January 2018

1 reference

Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis.

21 January 2018

1 reference

End-stage liver disease in a state prison population

21 January 2018

1 reference

Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C.

21 January 2018

1 reference

Prevalence and incidence of HIV, hepatitis B virus, and hepatitis C virus infections among males in Rhode Island prisons

21 January 2018

1 reference

Prevalence and incidence of hepatitis C virus infection among male prison inmates in Maryland

21 January 2018

1 reference

The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States

21 January 2018

1 reference

Watchful waiting with periodic liver biopsy versus immediate empirical therapy for histologically mild chronic hepatitis C. A cost-effectiveness analysis

21 January 2018

1 reference

Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation.

21 January 2018

1 reference

Cost effectiveness of interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis C.

21 January 2018

1 reference

Medical expenditures during the last year of life: findings from the 1992-1996 Medicare current beneficiary survey

21 January 2018

1 reference

Pretreatment evaluation of chronic hepatitis C: risks, benefits, and costs

21 January 2018

1 reference

Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1.

21 January 2018

1 reference

Treatment of chronic hepatitis C virus in the virginia department of corrections: can compliance overcome racial differences to response?

21 January 2018

1 reference

Therapy of interferon-induced depression in chronic hepatitis C with citalopram: a randomised, double-blind, placebo-controlled study

21 January 2018

1 reference

The effect of hepatitis C virus infection on health-related quality of life in prisoners

21 January 2018

1 reference

Cost Effectiveness of Peginterferon ??-2a Plus Ribavirin versus Interferon ??-2b Plus Ribavirin as Initial Therapy for Treatment-Naive Chronic Hepatitis C

21 January 2018

1 reference

The burden of infectious disease among inmates of and releasees from US correctional facilities, 1997

21 January 2018

1 reference

7 January 2021

Estimating future hepatitis C morbidity, mortality, and costs in the United States

1 reference

7 January 2021

Adopting more systematic approaches to hepatitis C treatment in correctional facilities

1 reference

7 January 2021

Treatment of hepatitis C

1 reference

7 January 2021

Identifiers

DOI

10.1002/HEP.22509

1 reference

19 August 2017

1 reference